|
 |
ZeaVision is pleased to announce the return of the 10mg zeaxanthin product
|
 |
| Boston, MA, June 28, 2007 6:00a.m. - 7:30a.m
:: ZeaVision sponsors an American Optometric Association Continuing Education Course: |
|
| St. Louis, MO, April, 2007
:: ZeaVision Adds Two More Prominent Doctors to its Advisory Board. |
|
| St. Louis, MO, August 28, 2006
:: ZeaVision Adds Three Leading Doctors to its Advisory Board. |
|
| St. Louis, MO August 11, 2006
:: Joseph M. Strout named new Chief Financial Officer and member of the Executive Committee for ZeaVision, LLC
|
|
| St. Louis, MO June 2, 2006
::Community Benefits from Eye Studies Conducted by the College of Optometry at the University of Missouri-St. Louis and ZeaVision
|
|
| ST. LOUIS, MO, May 24, 2006
::St. Louis Business Eyes Local Market As First In Country To Screen For AMD Risk
|
|
| May, 2006
::ZeaVision, LLC Announces Three New Business Developments
|
|
|
|
|
St. Louis MO, December 14, 2007--
ZeaVision is pleased to announce the return of the 10mg zeaxanthin product.
We have made significant
improvements with this product. It has an all-natural liquid formulation in a sealed, clear VeggieCap.
The capsule itself is smaller than the 5mg capsule, so it will be even easier to swallow. The clear
capsule will appear to be a reddish brown rather than the familiar orange you have been used to. This
color is a result of the zeaxanthin, as we have used no dyes or other colorants in the formulation or
capsule. We were able to reduce the size due to using a natural liquid formulation, where the zeaxanthin
is suspended in oil. This all-natural product is the result of receiving numerous customer requests
and we are happy to be able to offer such a product in response.
The source of our zeaxanthin is from the pepper used to make paprika (Capsicum annuum) and being suspended in
olive oil makes this zeaxanthin highly bioavailable, meaning more zeaxanthin is available for your body to utilize.
One note of caution: Since the zeaxanthin is in liquid form and the capsule is sealed, we do not advise cutting
or attempting to open the sealed capsule. The contents can stain, should any of the liquid get on your clothing, carpet, or furniture.
Due to the demand for the new 10mg product, the 5mg zeaxanthin-only product is being discontinued.
Order EyePromise® Ten
Boston, MA, June 28, 2007 6:00a.m. - 7:30a.m--
American Optometric Association Continuing Education Course:
The Importance of Macular Pigment, Measurement and Supplementation in a Clinical Practice.
Lecturer: S.Richer, O.D., Ph.D
This seminar will discuss the role of the macular pigments, zeaxanthin
and lutein, in ocular health. A review of basic science and supplementation
trials will be made, as well as the methods of measuring macular
pigment. Screening patients for low macular pigment will be discussed,
in addition to commercial developments that make this technology feasible
as a risk assessment tool in the clinical practice. Finally, the benefits
of supplementing patients with low macular pigment will be highlighted.
Seating is limited.
Sponsored by ZeaVision
Please visit ZeaVision at Booth # 214
For more information, click here or contact:
Rachel Voss, Area Sales Specialist
ZeaVision, LLC
314.415.1303
rvoss@zeavision.com
St. Louis, MO, April, 2007--
ZeaVision Adds Two Leading Doctors to its Advisory Board
ZeaVision, LLC announced the addition of two highly regarded optometrists to its business and scientific
advisory board; Glenda B. Secor, O.D., F.A.A.O. and Robert L. Davis, O.D., F.A.A.O. Both bring a wealth of
knowledge and experience to the ZeaVision team. ZeaVision organized its advisory board to assist in the
development and marketing of its new QuantifEYE® Program and line of professionally formulated vitamins for
the eye. The QuantifEYE® Program is the first in the industry that focuses on prevention of age-related eye
diseases, particularly macular degeneration, using a health risk assessment, macular pigment measurement and
retinal examination.
Dr. Robert Davis provides patient care at his eye care specialty practice, Davis Eyecare Associates,
located outside of Chicago, Illinois. Dr. Davis is a Fellow and Diplomate in the American Academy of
Optometry where he serves as subchair of the Membership Renewal Committee. He is also an active member
of the American Optometric Association, serving on its Industrial Relations Committee. He has worked
extensively in eye care management for over 25 years, spending time in research and development as well
as the clinical aspect of vision care. Dr. Davis has published and lectured extensively, as well as served
on the boards of industry publications. Over the past several years, he has provided consulting services
for a variety of companies in the management of eye care and the development of novel visual device modalities.
Dr. Davis graduated from the University of Iowa and received his Doctor of Optometry degree from the Illinois
College of Optometry.
Dr. Glenda Secor is currently in private practice in Huntington Beach, California. She is a Fellow of
the American Academy of Optometry, a Diplomate of the Cornea and Contact Lens Section, and is the current
Immediate Past Chair of the Cornea and Contact Lens Section. Dr. Secor is an active member of the American
Optometric Association, in recent years serving as the New Practitioner Practice Management Project Team Chair.
Her honors include being named California Optometrist of the Year in 2006 by the California Optometric Association,
being named one of the 50 Most Influential Women in Optical by Vision Monday in 2004, and being selected as Distinguished
Practitioner in Optometry for the National Academies of Practice in 2003. She has been a clinical investigator for numerous
manufacturers and has lectured, served on editorial boards, and published extensively. Dr. Secor received her Doctor of
Optometry degree from Indiana University.
“We are pleased to add Drs. Davis and Secor to our advisory board. Their expertise and experience in the
field of Optometry are certain to enhance the value ZeaVision offers the industry,” said Terry Hatfield,
President of ZeaVision, LLC.
For more information, please contact:
Rachel Voss, Area Sales Specialist
ZeaVision, LLC
314.415.1303
rvoss@zeavision.com
St. Louis, MO August 28, 2006--
ZeaVision Adds Three Leading Doctors to its Advisory Board
ZeaVision, LLC announced the addition of three reputable
optometrists to their business and scientific advisory board; Drs. Victor E. Malinovsky, Jack J. Yager and N. Rex Ghormley.
All bring a wealth of knowledge and experience to the ZeaVision team. ZeaVision organized their advisory board to assist
in the development and marketing of its new QuantifEYE® Program and line of professionally formulated vitamins for the
eye. The QuantifEYE® Program is the first in the industry that focuses on prevention of age-related eye diseases, particularly
macular degeneration, using a health risk assessment, macular pigment measurement and retinal examination.
Dr. Victor Malinovsky is a clinical professor at Indiana University College of Optometry in Bloomington, Indiana. He currently
teaches Retinal Clinical Service -- the development and coordination of retinal service for advanced education and training of
4th-year students and is the primary consultant to faculty and students on difficult ophthalmic disease patients. He received
his Doctor of Optometry degree from Indiana University.
Dr. Jack Yager has been part of a private practice since 1973 with Drs. Swanson, Sowers, Lee & Yager, P.A., in Orlando, Florida,
specializing in cornea and contact lenses and is the President and Office Administrator of his practice. He received his Doctor
of Optometry degree, and graduated with honors, from Ohio State University. Dr. Yager is the current President of the American
Academy of Optometry and is also a member and past president of the Florida chapter of the AAO (1983-1999).
Dr. Rex Ghormley is President of Vision Care Consultants in St. Louis, Missouri. He is a Fellow and past president of the
American Academy of Optometry and a Diplomat of the Academy’s Cornea & Contact Lens Section. Dr. Ghormley is an
adjunct Assistant Professor at the University of Missouri – St. Louis School of Optometry and an adjunct Instructor,
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine. Dr. Ghormley is a
graduate of the Southern California College of Optometry.
“These gentlemen are recognized leaders in the field of Optometry and are certain to greatly improve the value ZeaVision
offers the industry,” said Terry Hatfield, President of ZeaVision, LLC.
For more information, please contact:
Rachel Voss
ZeaVision, LLC
Area Sales Specialist
314-628-1000
rvoss@zeavision.com
|
St. Louis, MO August 11, 2006--
ZeaVision, LLC has announced Joseph M. Strout as the new Chief Financial Officer and member of the Executive Committee.
Mr. Strout has held numerous senior level finance positions in the consumer products, steel, computer hardware, retail footwear and agricultural
manufacturing industries. Most recently, from 1989 to 2005, Mr. Strout served as Director of Financial Planning and Analysis, Director of Internal
Audit and Director of New Business Development for the Solae Company, LLC.
In addition to serving as the CFO and as a member of the Executive Committee, Mr. Strout will be responsible for the Controllership and Treasury
functions of the company which includes accounting, financial statement preparation, cash and insurance management in addition to benefits administration.
Mr. Strout is also active in the St. Louis community as a member of the St. Louis Children’s Hospital Family Advisory Board whose focus is
Family Centered Care at the hospital. He is also a member of the United States Field Hockey Association Nominating and Governance Committee
which is the National Governing Body of for U.S. Field Hockey for the U. S. Olympic Committee based in Colorado Springs, CO.
Mr. Strout and his wife reside in Creve Coeur and have two grown children.
For more information, please contact:
Rachel Voss
ZeaVision, LLC
Area Sales Specialist
314-628-1000
rvoss@zeavision.com
|
St. Louis, MO June 2, 2006—
Community Benefits from Eye Studies Conducted by the College of Optometry at the University of Missouri-St. Louis and ZeaVision
ZeaVision, LLC and the College of Optometry at the University of Missouri-St. Louis announce two trials that offer to seek and
document the ocular benefits of increasing the natural pigmentation of the eye. There is no fee to determine your eligibility and
those enrolled will receive supplements and study visits at no charge.
The first trial addresses Photophobia, or excessive light sensitivity. People with this condition may experience pain, tearing, and
squinting when exposed to sunlight or a well-lit room. The clinical objective of this trial is to determine if supplementation with the
key nutrient, zeaxanthin (zee-uh-zan-thin), reduces photosensitivity or the discomfort from bright light. Research suggests that the
symptoms of light sensitivity may be related to low levels of carotenoids in the eye. Carotenoids are the natural, fat-soluble pigments
found in certain plants and vegetables that provide them with their bright red, orange, or yellow coloration and protect them from light
damage. They serve as antioxidants, and are proven to be important for eye health. Zeaxanthin and lutein are the two carotenoids
that make up the pigment in the macula. Researchers believe that increased macular pigment — specifically zeaxanthin — may reduce light sensitivity.
The second trial examines how successful zeaxanthin and lutein supplementation is at raising macular pigment levels. Both pigments are
found in high concentration in the macula and are thought to protect the macula from damage due to high energy light waves and free
radicals. To date, studies have indicated that low macular pigment is associated with a higher risk for age-related macular degeneration
(AMD), a leading cause of blindness. ZeaVision recently introduced a program called QuantifEYE® to help identify potential risk for
AMD by evaluating a person’s health history, including genetics, diet, macular pigment assessment and retinal examination. ZeaVision’s
device, used in this trial, measures macular pigment optical density (MPOD) using heterochromatic flicker photometry. The trial will determine
the resulting level of macular pigment increase after supplementing patients with a leading edge formulation containing zeaxanthin and lutein.
UMSL College of Optometry is recruiting volunteers who have low macular pigment levels.
Professor Carl J. Bassi, Ph.D. is an Associate Professor at the College of Optometry at UMSL and is leading the trials.
St. Louis-based ZeaVision, LLC, founded in December, 2000, is a nutraceutical company with a focus on eye health. They are also a
leader in the fight against vision loss associated with macular degeneration. ZeaVision developed and markets the EyePromise®
brand of dietary supplements containing zeaxanthin, to help reduce risk for developing AMD, or to help slow or stop the
progression of AMD in those already diagnosed.
Volunteers are still sought for both trials:
Zeaxanthin and Photophobia Trial
Volunteers who rate themselves very light sensitive to the point of serious discomfort in daylight are being recruited. If you qualify,
you must commit to four subsequent visits to the College of Optometry at UMSL and would receive either zeaxanthin (20 mg) or a placebo
for six months. The optometric exams and supplements will be provided. This equates to an approximate value of $400.00. Volunteers
must be willing to be examined at the College of Optometry at UMSL four times over a six month period and comply with the procedures.
On the first visit you will receive a complete eye examination and three other tests to measure your sensitivity to light. On the subsequent
three visits (at one month, three months, and six months follow-up) you will only receive the three measures of light sensitivity and questionnaires.
Raising MPOD Scores Trial
This trial will evaluate the success of zeaxanthin and lutein supplementation in raising the MPOD levels in those volunteers who may have low
baseline measurements. Volunteers for this trial will be required to visit the College of Optometry at UMSL on three occasions over a six month
period. All optometric exams and supplements, valued at approximately $300.00 will be provided. On the first visit you will receive a complete eye
examination and three other tests to measure your sensitivity to light. On the subsequent two visits (at three months and six months follow-up)
you will only receive the three measures of light sensitivity and questionnaires.
If interested in volunteering: Please contact:
Kathleen Boland, OD
College of Optometry at the University of Missouri - St. Louis
8001 Natural Bridge, Road
St. Louis, MO 63121-4499
(314) 516-6229
bolandk@umsl.edu
For more information, contact:
Rachel Voss, Area Sales Specialist
ZeaVision, LLC
314.628.1000
rvoss@zeavision.com
|
St. Louis, May 24, 2006--
St. Louis Business Eyes Local Market as First in Country to Screen For AMD Risk.
ZeaVision, LLC has introduced a proprietary program for Eye
Care Professionals that can quickly and easily assess risk for Age-Related Macular Degeneration (AMD). Currently
available only in the St. Louis market, ZeaVision expects to introduce this program, called QuantifEYE®, nationally,
with plans to expand into key European markets starting in 2007.
AMD is fast reaching epidemic proportions with 15 million Americans currently affected. That number is expected to
double by 2020 as Baby Boomers reach their 60’s and 70’s. AMD is a disease affecting the macula in the retina of the
eye, and is the leading cause of blindness in this age group. Once symptoms are noticeable, damage has already
occurred. AMD’s affects are both permanent and irreversible.
ZeaVision’s QuantifEYE® Program is the first of its kind in the world to quickly, conveniently, and inexpensively identify
potential risk of AMD (and other diseases of the eye). The QuantifEYE® Program, through early detection and mitigation
of risk for AMD, has potential to significantly reduce Medicare costs for a disease that is growing in scope and burden.
Doctors can screen patients at an early age and can now monitor Macular Pigment Optical Density (MPOD) levels as part
of their eye care routine. Low macular pigment has been associated with high risk for AMD. The device being introduced
can measure pigment in the macula – something only available at research facilities – until now.
For patients that are found to have low levels of macular pigment, suggesting a change in diet along with zeaxanthin-
and lutein-based supplements can positively impact risk. Prevention is key, and early risk identification can make the
difference in their patients’ quality of life.
ZeaVision, LLC, a St. Louis-based company, founded in December, 2000, is committed to leading the fight against
vision loss associated with Macular Degeneration. Dennis Gierhart, Ph.D., Chairman and CEO/CSO, has dedicated
the last 20 years to research and development of products and services for prevention of AMD.
For more information, please contact:
Rachel Voss
ZeaVision, LLC
Area Sales Specialist
314-628-1000
rvoss@zeavision.com
|
St. Louis, May, 2006--
ZEAVISION, LLC ANNOUNCES THREE NEW BUSINESS DEVELOPMENTS
ZeaVision, LLC of St. Louis, Missouri, recently announced three new business developments: A third patent
licensing agreement, a round of private financing, and a new business initiative.
ZeaVision’s President, Mr. Terry Hatfield, said “These three developments position ZeaVision for aggressive
business growth in 2006 and beyond.”
ZeaVision announced their third licensing agreement in three years with Kalsec, Inc. of Kalamazoo, Michigan.
They also hold agreements with Chrysantis (Ball Horticultural) and DSM Nutritional Products (formerly Roche Vitamins).
The patent license allows Kalsec to sell bulk zeaxanthin to the supplement and food industries and provides
a “pass through” license to buyers of Kalsec’s ZeaGold™ form of zeaxanthin, for daily dosages of up to 4 mg of zeaxanthin.
Zeaxanthin (zee-uh-zan-thin) is a macular pigment that a growing body of science indicates is important in
reducing the risk of cataract formation and age-related macular degeneration (AMD), the two most prevalent chronic eye diseases.
The completion of a private round of financing will add $2 million of capital from local private investors.
Ongoing revenue, licensing fees, and this private round of equity allows ZeaVision to properly launch
its newest business initiative for eye care professionals, involving a measurement device and a
professional line of ophthalmic supplements. This device provides a simple, non-invasive measurement
of retinal levels of the macular pigments zeaxanthin and lutein. Patients with low macular pigment levels
can now increase macular pigment density with professionally designed ophthalmic supplements.
ZeaVision introduced the QuantifEYE® device and eye health program in the St Louis area in March,
and plans a broad geographic expansion in the near future.
The QuantifEYE® device, which ZeaVision has exclusive worldwide distribution rights from a European
concern, will allow simple measurements of the retinal levels in less than 5 minutes. The professional line
of supplements (EyePromise® Restore) are protected by ZeaVision’s strong patent estate.
The ZeaVision web site, www.eyepromise.com, points out the absence of effective medical or surgical
procedures to treat the dry form of AMD, which represents 90% of all cases (15 million cases in the U.S. alone).
Mr. Hatfield stated that, “The National Eye Institute’s AREDS clinical trial documented that dry macular
degeneration has responded to nutritional therapy.” Dr. Dennis Gierhart, Ph.D., founder of ZeaVision, LLC,
also pointed out that “Zeaxanthin is the most important pigment found in the center of the macula where it
exists in a 2 to 1 ratio of zeaxanthin to lutein.”
In 2005, the Lewin Group reviewed the research literature on zeaxanthin and lutein and studied the impact
of these nutrients on the quality of life and health care costs for adults over age 65. The estimated savings
relative to a daily intake of 6 to 10 mg per day of these carotenoids would result in more than $2.5 billion in
savings to the Medicare system over five years.
ZeaVision, LLC, is a pioneer in the development of nutrition-based solutions for the prevention and treatment
of AMD and cataracts. They have developed a wide range of intellectual property around zeaxanthin, in both
eye and skin health, and continue to work with scientific leaders in these areas to expand on the building body
of proof that zeaxanthin is a critical nutrient for human health. For more information on zeaxanthin and the products
that are being marketed by ZeaVision, visit EyePromise.com or call 1-800-508-9022.
For more information, please contact:
Terry Hatfield, President
ZeaVision, LLC
Phone: 314-628-1000
Fax: 314-628-1010
E-mail: thatfield@zeavision.com
|
September 9, 2005
Washington University study looks at sunscreen vitamin
Could a substance that gives carrots and tomatoes their color keep you from turning red in the sun?
Researchers at Washington University School of Medicine are convinced the possibility exists, so they're
looking for volunteers to sign up for a "sunscreen vitamin" study.
The vitamin is zeaxanthin (pronounced ZEE-zan-thin). Like beta-carotene and lycopene, it's one of
the many carotenoids or natural plant pigments found in fruits and vegetables.
Dr. Michael Heffernan, assistant professor of dermatology and director of the Dermatology Clinical
Trials Unit at Washington University, wants to see whether it offers a sun protection factor similar
to what you currently only find in a bottle of sunscreen.
Supplements of zeaxanthin apparently come with no significant side effects. Heffernan said it has
an excellent safety profile and is well-tolerated in studies done in humans and animals.
In the zeaxanthin study, volunteer subjects are asked to take 30 milligrams of the substance once
a day. Small patches of skin less than one square inch are then exposed to medical-grade sunlight
to see if the supplement offers any sun protection over time.
One word of caution: don't try this at home. Heffernan says the study is still in a very
early stage, and there's not enough data to say whether zeaxanthin really works, or at
what dose. But he hopes one day this could help the millions of people who shun sunscreen
or don't use enough.
Potential volunteers should be fair-skinned and prone to sunburn. For information, call 314-362-9853.
Kay Quinn is an anchorwoman and reporter at KSDK (Channel 5).
read the KSDK article here.
About ZeaVision, LLC
Based in St. Louis, ZeaVision, LLC (www.zeavision.com) developed and markets ZeaVision, a dietary supplement containing
zeaxanthin and formulated to help prevent and/or impede the progression of macular degeneration. The Company holds
multiple patents on the ZeaVision formula, which is available without a prescription in both 10mg and 3mg supplement.
Media Contact
Malcolm Grover
ZeaVision, L.L.C.
(314)628-1000
E:mail: msgrover@zeavision.com
April 7, 2004
ZeaVision and DSM Nutritional Products Reach Patent Dispute Settlement Agreement
ZeaVision, L.L.C.
ST. LOUIS, MO - ZeaVision, LLC and DSM Nutritional Products have jointly announced a settlement agreement
resolving a patent dispute for the sale and promotion of zeaxanthin. Zeaxanthin (pronounced zee-uh-ZAN-thin)
is a dietary carotenoid found in the macula, the central part of the retina in the eye that is responsible for
most fine vision. Zeaxanthin is thought to be an important nutrient for eye health and has other health-related implications.
According to the settlement, ZeaVision has dismissed its patent infringement suit that originally began in February 2003
against, among others, defendant Roche Vitamins Ltd, a Swiss DSM Nutritional Products company, in the U.S. District Court
in St. Louis, MO. Under the settlement, DSM receives a limited, non-exclusive license to ZeaVision's patents related to zeaxanthin.
Terry Hatfield, President, ZeaVision LLC, said in a statement, We are pleased that both companies can now
focus on the development of zeaxanthin and we think it is a positive development for consumers concerned
with eye health and the millions of people that suffer from macular degeneration. Bob Hartmayer, Chief
Operating Officer, DSM Nutritional Products, said that DSM, as the market leader for carotenoids, can
now focus on the development of the zeaxanthin market. We are very excited about the growth potential
for this product and believe that zeaxanthin further strengthens our position as the leading innovative
supplier to the Nutritional market.
ZeaVision LLC, based in St. Louis, MO, is focused on the development and marketing of zeaxanthin-based
supplements for the eye. Dietary zeaxanthin is considered to be a critical nutrient in eye health and
in the fight against macular degeneration. Zeaxanthin is also a highly effective antioxidant that
provides additional health benefits throughout the body. For further information, please visit
www.zeavision.com or contact ZeaVision at 314-628-1000.
DSM Nutritional Products, the successor to Roche's Vitamins & Fine Chemicals Division, is the
world's leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food,
pharmaceutical and cosmetic industries. The company will maintain its tradition as a pioneer
in the discovery of new products, new formulations and attractive applications for all industry
segments. For further information, please visit www.dsmnutritionalproducts.com
DSM DSM is active worldwide in life science and nutritional products, performance materials
and industrial chemicals. The company creates innovative products and services that help
improve the quality of life. DSM's products are being applied in a wide range of end markets
and applications such as human and animal nutrition and health, cosmetics, pharmaceuticals,
automotive and transport, coatings, housing and electrics & electronics (E&E). The group has
annual sales (pro forma including the recent acquisition - renamed DSM Nutritional Products)
of approximately EUR 8 billion and employs in the region of 25,000 people around the world.
DSM ranks among the global leaders in many of its fields. DSM is headquartered in the
Netherlands, with locations in Europe, Asia and the Americas. More information about
DSM can be found at www.dsm.com.
For more information:
ZeaVision, L.L.C.
Terry Hatfield, President
tel. 314-628-1000
fax 314-628-1010
E:mail: thatfield@zeavision.com
November 13, 2003
ZeaVision Receives Allowance of European Patent on Zeaxanthin for Macular Degeneration
ZeaVision LLC
ST. LOUIS (November 13, 2003) The European Patent Office has published an official notice that it has
fully examined and approved a major patent application belonging to ZeaVision, L.L.C. (St. Louis, MO)
This European patent, which will be enforceable in Great Britain, France, Germany, and numerous other
European nations, greatly increases ZeaVision's patent rights covering formulations and uses for
zeaxanthin, a natural carotenoid that plays a major role in protecting human eyesight.
Zeaxanthin is one of two pigments found in the "macula," a yellow-colored disc, at the
center of the human retina. The macula is about the size of an eraser on the end of a pencil.
Lutein is the other pigment in the macula; however, zeaxanthin has certain traits that render
it better than lutein at cellular and retinal deposition, absorbing damaging light, and
neutralizing toxic free radicals. Therefore, zeaxanthin is deposited in higher concentrations
in the exact center of the retina, which is crucial for vision. Degeneration of the macula
is the leading cause of blindness among the elderly.
"We are extremely pleased that the European Patent Office has accepted and supported the
claims and property rights set forth in our patent application," said Dennis Gierhart,
CEO & Chairman of ZeaVision. "We have been working on that application for years, with
an entire team of lawyers, and the European Patent Office had a committee of patent
examiners studying and challenging it. We overcame every challenge and we are proud
of the result." Similar patents issued in the United States are being litigated by
ZeaVision, in a lawsuit against Roche Vitamins (the manufacturer) and one retailer.
Two other retailers initially were sued, but they settled with ZeaVision under a license
agreement. Roche Vitamins was recently acquired by DSM, a Dutch chemical company.
About ZeaVision, LLC
Based in St. Louis, ZeaVision, LLC (www.zeavision.com) developed and markets ZeaVision, a dietary supplement containing zeaxanthin and formulated to help prevent and/or impede the progression of macular degeneration. The Company holds multiple patents on the ZeaVision formula, which is available without a prescription in both 10mg and 3mg supplement.
Media Contact
Malcolm Grover
ZeaVision, L.L.C.
(314)628-1000
E:mail: msgrover@zeavision.com
October 16, 2003
ZeaVision, L.L.C. Announces New President
ZeaVision LLC
ST. LOUIS - (October 16, 2003) - October 13, 2003 ZeaVision, L.L.C., a nutraceutical company with a
focus in eye health announces Mr. Terry B. Hatfield as President. Mr. Hatfield brings to ZeaVision
over 30 years experience in the food and nutraceutical business. Most recently, Mr. Hatfield has
been involved with M&A activities and consulting. Previously, he held a number of senior executive
positions with Ralston Purina and Dupont in Protein Technologies International division, where his
last position was Co-President, responsible for sales, marketing, application technology and manufacturing.
In addition to his responsibilities as President, Mr. Hatfield will be a key member of the
Executive Committee, joining the Chairman and CEO, Dennis L. Gierhart, PhD and Vice Chairman,
Steven N. Frank. "We are very excited about having Terry on our team. He brings a wealth of
experience to ZeaVision and provides us with the expertise to bring our company to the next level.
The addition of Terry will allow all of us to focus more on the key strategic issues that will lay
the groundwork for continued growth and success", said Gierhart.
Hatfield, 55, holds a B.A. in Chemistry from the University of Louisville, as well as numerous
post grad and professional studies in general management.
"I am truly excited about joining the ZeaVision team. This is an outstanding opportunity with an
organization that has tremendous potential with a patent-protected product that offers significant
health benefits. I am looking forward to working with the talented team that ZeaVision has assembled."
About ZeaVision, LLC
Based in St. Louis, ZeaVision, LLC (www.zeavision.com) developed and markets ZeaVision, a dietary supplement containing zeaxanthin and formulated to help prevent and/or impede the progression of macular degeneration. The Company holds multiple patents on the ZeaVision formula, which is available without a prescription in both 10mg and 3mg supplement.
Media Contact
Malcolm Grover
ZeaVision, L.L.C.
(314)628-1000
E:mail: msgrover@zeavision.com
September 18, 2003
ZeaVision Settles Patent Infringement Case with Non-Roche Defendants
ZeaVision LLC
ZEAVISION SETTLES PATENT INFRINGEMENT CASE WITH NON-ROCHE DEFENDANTS
ST. LOUIS -- (Sept. 18, 2003) -- Two companies sued by St. Louis based ZeaVision,
L.L.C., have agreed to settle claims made against them in ZeaVision's patent
infringement suit filed earlier this year in the U.S. District Court for the Eastern District
of Missouri. Named as defendants in the lawsuit are Roche Vitamins, Inc., of Parsippany, NJ,
its two corporate affiliates headquartered in Basel, Switzerland, F. Hoffmann La-Roche AG and
Roche Vitamins Ltd., and three dietary supplement companies: Geres Dengle Co. of Spencerport,
NY, Vitamin Science, Inc., of Long Island, NY, and Life Extension Foundation, Inc., of Fort
Lauderdale, FL. Roche's Vitamins and Fine Chemicals Division is being sold to DSM, a multinational
company based in the Netherlands, and a leading producer of life science products, performance
materials, and industrial chemicals. The other defendants are companies engaged in sales of
various nutritional supplements and other products. The lawsuit alleges that sales by the non-Roche
defendants of dietary supplements containing zeaxanthin (pronounced zee-uh-ZAN-thin) infringe
certain composition and method of use U.S. patents held by ZeaVision pertaining to zeaxanthin.
The suit also charges the Roche defendants with infringement of ZeaVision's patents by Roche's
marketing and sale of zeaxanthin products. In the settlement, Geres Dengle Co. and Vitamin
Sciences, Inc., have signed consent decrees admitting the validity and enforceability of
ZeaVision's patents. Both companies agreed to cease and desist from further infringement.
As part of the settlement, ZeaVision has agreed to grant the settling defendants non-exclusive,
royalty-bearing licenses to market and sell dietary supplements containing zeaxanthin in doses not
exceeding 2 mg per day. For the defendants that have not settled, ZeaVision is seeking damages for
willful infringement of its patents. "ZeaVision has spent many years investing in dietary zeaxanthin
and will protect and defend its associated intellectual property portfolio when it is threatened,"
said Dr. Dennis L. Gierhart, chairman and chief executive officer of ZeaVision (www.zeavision.com).
"Our dietary zeaxanthin patents are extremely valuable corporate assets, and this suit reflects
our determination to protect their value." In April 2002 ZeaVision launched the sale of its
patent-protected dietary supplements containing zeaxanthin. Both a carotenoid and antioxidant,
zeaxanthin is a naturally occurring pigment found in many fruits and vegetables that help
protect the retina from the damaging effects of sunlight and oxidative stress and free
radicals. As a critical eye-health nutrient, zeaxanthin promotes eye health and helps
protect the retina against macular degeneration. The benefits of dietary zeaxanthin
are supported by a growing body of science from human and animal studies, including
a human study from the Medical Research Council Environmental Epidemiology Unit,
University of Southampton, U.K. published in June 2003, which suggests that higher
levels of zeaxanthin in blood serum may be more important in preventing or stabilizing
age-related macular degeneration than lutein, which has been on the market since the
1990s. Among other things, the study concluded "Low blood level of zeaxanthin -- not
lutein, is significantly associated with the risk of developing age-related macular
degeneration." ZeaVision, an emerging nutraceutical company based in the St. Louis
area, holds a number of patents on the manufacture, use and composition of dietary
zeaxanthin in the U.S., Australia, Canada, China, South Africa, and South Korea. It
also has pending patent applications related to zeaxanthin in the U.S., Europe, and
several other countries. The patents-in-suit are U.S. Patent No. 5,747,544, ,
(number 5,747,544),which relates to the use of zeaxanthin for macular degeneration,
and U.S. Reissue Patent No. 38,009,(number Re-38,009), which relates to compositions,
pills, tablets, and capsules containing zeaxanthin.
June 9, 2003
Study Links Zeaxanthin to Macular Health
ZeaVision LLC
“Low blood level of zeaxanthin -- not lutein, is significantly associated with the risk
of developing age-related macular degeneration.”
ST. LOUIS -- (June 9, 2003) -- A recent human study from the Medical Research Council
Environmental Epidemiology Unit, University of Southampton, U.K. provides scientific
evidence that a key nutrient and a strong antioxidant member of the carotenoid family,
called zeaxanthin (zee-ah-ZAN'-thin,) may be far more important in preventing or stabilizing
macular degeneration than previously realized. Macular pigment, which is primarily composed
of lutein and zeaxanthin, is thought to protect the retina from damage due to light exposure
and oxidative stress. Additionally, it has been shown that a high macular pigment density
helps to retain visual sensitivity as we age and evidence indicates that raising the intake
of dietary zeaxanthin can increase macular pigment. The macular pigment acts like “sunglasses”
by protecting the critically important central sight from damaging light waves. The distribution
of lutein and zeaxanthin in the eye may indicate they have different functions. Zeaxanthin is the
dominant component in the center of the macula, while lutein dominates at the outer edges. The eye
is selective and preferentially places dietary zeaxanthin in the very center of the macula, the most
critical area for central vision with the greatest need for protection. This selective uptake of
zeaxanthin occurs even though lutein is more available in the diet by a 20:1 ratio. Previous
investigations may have obscured evidence of zeaxanthin’s greater protective role by looking
at the two carotenoids together, rather than separately. Although both of these carotenoids
protect the retina, zeaxanthin has been shown to be a better photoprotector and a recent animal
study supports the photoprotective activity of zeaxanthin. Additionally, zeaxanthin’s chemical
structure makes it a much more effective antioxidant than lutein. The human study concluded that
decreased blood plasma zeaxanthin, but not blood plasma lutein, is significantly associated with
the risk of age-related macular degeneration. This correlation strongly indicates that a high
level of dietary zeaxanthin intake may directly affect the risk of developing macular degeneration.
Increasing intake through diet or supplementation may help to slow down or stop vision loss with
those who have been diagnosed with AMD.
The research team included:
** Catharine R. Gale, Nigel F. Hall, David I.W. Phillips and Christopher N. Martyn
Study Abstract
http://www.iovs.org/cgi/content/abstract/44/6/2461
February 25, 2003
United States Patent Office Issues Another Patent to Strengthen ZeaVision's Patent Portfolio
ZeaVision LLC
U.S. Patent and Trademark Office Published ZeaVision's Patent Reissue
St. Louis -- (Feb 25, 2003) -- The U.S. Patent and Trademark Office has issued yet another
patent that broadens ZeaVision's patent portfolio on zeaxanthin-containing products. In this patent,
U.S. Reissue Patent No. 38,009 (number Re-38,009), the U.S. Patent and Trademark Office reconfirmed
the patentability of ZeaVision's patent claims for unit dosages of at least about 3.0 mg of zeaxanthin.
Additionally, ZeaVision's patent protection was further expanded to cover any unit dosage of at least
about 0.5 mg of zeaxanthin OR amounts that cause a detectable increase of zeaxanthin concentration in the retinal tissue.
November 11, 2002
Study Demonstrates Essential Role of Zeaxanthin in Eye Health
Schepens/Harvard study provides direct proof of dietary nutrient's essential role in protecting the retina
from the damaging effects of light
BOSTON -- (Nov. 11, 2002) -- Research performed at Schepens Eye Research Institute and Department of Ophthalmology,
Harvard Medical School has established that the dietary zeaxanthin (zee-uh-zan'-thin) plays an essential role in protecting
the retina of the eye from the damaging effects of light.
From the many carotenoids in the diet, the human retina selectively accumulates only two: zeaxanthin and lutein.
Their concentration is so high in the macula, (the retinal region responsible for fine visual activities) that the
carotenoids are visible as a dark yellow spot called the macular pigment. Because these carotenoids absorb blue
light, and because they are powerful antioxidants, scientists have hypothesized that they protect the retina.
Working with quail as an animal model, the Schepens project provided the first direct experimental evidence that
carotenoids do protect the retina.
Macular pigment has been implicated as a risk factor in age-related macular degeneration (AMD), the most prevalent
cause of vision loss in the elderly. Vision loss in AMD is due to the irreversible death of photoreceptors and/or
the invasion of leaky, unwanted blood vessels into the retina. At advanced stages of this progressive disease,
everyday activities such as reading, driving, or even seeing the face of a loved one become impossible.
It is estimated that more than 17 million Americans may have symptoms of AMD and that 2 million having functional
blindness; 500,000 new cases are diagnosed each year. Some clinical studies have found evidence that people with
higher dietary or serum levels of zeaxanthin and lutein had reduced risk for advanced stages of age-related macular
degeneration, but others have found no association.
Significantly lower macular pigment levels have been found in people with factors known to increase risk for AMD
(e.g. smoking), in eyes with AMD, and in eyes at high risk for AMD. Epidemiologic studies have shown that people
with higher dietary or plasma lutein/zeaxanthin have reduced risk for advanced stages of AMD. It is not yet clear
whether the reduced risk for AMD is due to lutein/zeaxanthin or due to some other nutrient in the plants containing
carotenoids. The Schepens work has clearly shown that the carotenoids protect the retina from light damage in animals.
Some studies, but not all, have identified light damage as a risk factor in AMD.
To test this hypothesized protection, the team selected Japanese quail, because the retina resembles the human macula
in having more cone photoreceptors than rods, and in highly selective accumulation of zeaxanthin and lutein from their
diet. Rodents were not studied because their retinas have very few cones and do not accumulate carotenoids. The studies
examined the effect of manipulating dietary carotenoids on light damage to retinas. C. Kathleen Dorey, principal
investigator formerly with Schepens and now with R&D Consulting, and her colleagues raised quail on diets that were
normal, carotenoid-deficient, or carotenoid-deficient supplemented with high doses of zeaxanthin.
In the short-term study, reported in the November 2002 issue of Investigative Ophthalmology and Visual Science (IOVS),
the team divided the carotenoid-deficient quail into two groups, and for one week preceding light damage, they fed one
group zeaxanthin-supplemented diet. The study established that photoprotection was strongly correlated with the concentration
of zeaxanthin in the retinas of the quail. Retinas with low concentrations of zeaxanthin had suffered severe light damage,
as evidenced by a very high number of apoptotic photoreceptor cells, while the group with high zeaxanthin concentrations
had minimal damage. Apoptosis is programmed cell death, the final common pathway for photoreceptor death in retinal degeneration.
In the long-term study, reported in the November 2002 issue of Experimental Eye Research, groups of quail were raised for
six months on carotenoid-deficient, normal or zeaxanthin-supplemented diets before exposure to brighter light. The results
showed extensive damage to the retina in the carotenoid-deficient animals, as evidenced by large numbers of both dying
photoreceptors and gaps or "ghosts" marking sites where photoreceptors had died. The group of quail with normal dietary
levels of zeaxanthin showed significantly less retinal damage than did the zeaxanthin-deprived group, while the quail
group receiving high levels of zeaxanthin had few ghosts in their retinas.
These experiments by Dr. Dorey's team showed protection of both rod and cone photoreceptors. The research further
demonstrated that retinas were protected by both zeaxanthin and another antioxidant, vitamin E. Damage in these
experiments was clearly reduced by zeaxanthin and tocopherol, but not lutein. Further experiments would be needed
to determine whether elevated lutein would offer protection.
These results are reminiscent of the early 20th century discovery of the role of vitamins. In those
experiments, extensive efforts were made to show that dietary deficiency of a compound caused health problems
that were reversed by adding the substance back to the animal's diet.
The results of the Schepens studies come on the heels of the Age Related Eye Disease Study (AREDS), sponsored by
the National Eye Institute of the National Institutes of Health, which concluded that daily consumption of a formula
containing high doses of dietary antioxidants are effective in slowing the progression of AMD in patients with
advanced stages of the disease. It is noteworthy that zeaxanthin and lutein, two antioxidants selectively concentrated
by the macula, were not commercially available when the AREDS began and were, therefore, not able to be included in that study.
Commenting on the implications of the Schepens studies, Dr. Dorey said: "AMD is a multi-factorial disease clearly influenced
by both genetic (family history) and environmental factors (diet, and possibly light history). The retina is constantly
exposed to oxidative injury, a leading candidate for initiating or accelerating retinal degeneration. Zeaxanthin is well
suited to its role in maintaining retinal health, and may be an important strategy to prevent or intervene in macular
degeneration. It accumulates in the macula where it absorbs harmful blue wavelength light, and it accumulates in the RPE
and the most vulnerable portions of the photoreceptors where its potent anti-oxidant capacity can prevent oxidative
damage, a problem that increases with aging."
"Our studies showed that light damage was strongly influenced by the amount of zeaxanthin in the retina, and that
significantly greater retinal protection was provided at dietary levels higher than those normally occurring in the
diet. Zeaxanthin has been extensively studied for safety and has been reviewed as a dietary ingredient by the FDA.
We hope this work further stimulates interest in clinical trials, and believe that zeaxanthin has a potential to
eventually complement other strategies to improve the treatment of this vision-robbing disease."
###
The research team included:
** Lauren R. Thomson, M.D. Yoko Toyoda, M.D. Z-Y Wong, M.D., Francois C. Delori, Ph.D., and C. Kathleen Dorey, Ph.D. (now with R&D Consulting) at Schepens Eye Research Institute.
** Kevin M. Garnett, BS, MBA at Applied Food Biotechnology, Inc. (O'Fallon, Mo.)
** Kimberly M. Cheng, Ph.D. and Cathleen R. Nichols at Department of Animal Sciences, University of British Columbia (Vancouver)
** Neal E. Craft, Craft Technologies, Inc. (Wilson, N.C.)
Media Contact:
Liz Roop
RFB Communications Group, Inc.
(813) 259-0345
email
July 18, 2002
Nature's Sunglasses™: ZeaVision's dietary supplement offers the eye protection from sun damage
ST. LOUIS -- (July 18, 2002) Summer health alerts generally focus only on the importance of protecting our skin from sun damage.
But our eyes are also in need of daily protection from the sun's ultraviolet rays, which have been linked to cancer, cataracts
and even macular degeneration.
Now, there is a safe, natural way to protect them from the inside. Called ZeaVision, it's a dietary supplement containing
zeaxanthin, a strong antioxidant with superior light-filtering properties that is one of two yellow carotenoids in the retina.
Studies have shown that zeaxanthin is preferentially absorbed from food and settles in the eye's lens and, to a greater extent,
in the center of the macula.
Research suggests that zeaxanthin protects the eye from the damaging effects of sunlight because it specifically absorbs ultraviolet
and blue light, the most damaging and highest energy wavelengths of light. UV radiation in sunlight has been linked to eye cancers,
corneal sunburns, photokeratitis, cataracts and solar retinopathy and may also be linked to macular degeneration.
Zeaxanthin occurs naturally in foods such as corn, oranges, eggs and certain leafy green vegetables. Yet it is difficult to
maintain healthy levels of zeaxanthin through diet alone, and other supplements currently on the market that contain zeaxanthin
in combination with lutein and/or other antioxidants haven't demonstrated a capacity to do so, either.
"In fact, ZeaVision is the only product on the market shown to deliver sufficient levels of zeaxanthin to the eye. And that is so
important, because studies have shown that without proper nutritional intake, the levels of zeaxanthin in the eye decreases over
time, leaving them more susceptible to the ravages of sunlight," says Dennis L. Gierhart, Ph.D., chairman and CEO of ZeaVision
L.L.C. "ZeaVision, however, acts like 'nature's sunglasses,' shielding the eyes while providing a critical nutrient they need
to repair and heal."
Steven N. Frank, vice chairman and president of ZeaVision: "Additional research is needed to understand the full impact zeaxanthin
has on eye health, which is why we actively support and participate in ongoing research. However, there is evidence to suggest
that, when taken properly, ZeaVision can restore zeaxanthin to healthy levels, enabling the eye to protect itself from the damaging
effects of sunlight and aging."
Available without a prescription, ZeaVision comes in two dosages, a 10 mg supplement for people who have been diagnosed with or
are at increased risk for macular degeneration, and a 3 mg supplement for people at low or no risk who want to maintain healthy
zeaxanthin levels. ZeaVision has been extensively tested and found to be safe with no known side effects or drug interactions.
Limited human volunteer trials have also shown no negative interaction with fat-soluble vitamins. It is available on the Company's
website at www.zeavision.com or by calling toll-free (888) 875-EYES (3937).
About ZeaVision L.L.C.
St. Louis, ZeaVision L.L.C. (www.zeavision.com) developed and markets ZeaVision, a dietary supplement containing zeaxanthin and formulated to help prevent and/or impede the progression of macular degeneration. The Company holds three patents on the ZeaVision formula, which is available without a prescription in both 10 mg and 3 mg supplements.
Media Contact
Liz Roop
RFB Communications Group, Inc.
(813) 259-0345
email
June 11, 2002
ZeaVision's Zeaxanthin-based Supplement Offers Hope To Macular Degeneration Patients and Their Families
ST. LOUIS — (June 7, 2002) — Each year, an estimated 500,000 people receive the heart-breaking diagnosis of macular degeneration,
the leading cause of blindness in individuals age 55 and older. It's a particularly devastating diagnosis, because little can be
done as the disease slowly robs patients of the precious sight and quality of life.
That is changing, however, as more is learned about zeaxanthin, a strong antioxidant with superior light-filtering properties and
one of two yellow carotenoids in the retina. Studies have shown that zeaxanthin is preferentially absorbed from food and settles
in the center of the macula. Now, a growing body of research suggests that increasing the level of zeaxanthin in the macula may
slow and even prevent macular degeneration by providing a critical nutrient the eye needs to protect and possibly heal.
It is also the main ingredient in ZeaVision, a dietary supplement and the only product on the market shown to deliver sufficient
levels of zeaxanthin to the macula. There, it helps protect the eye from the damaging effects of aging and sunlight.
"Essentially, ZeaVision acts like 'nature's sunglasses,' shielding the eyes while allowing them to repair and heal," says Dennis
L. Gierhart, Ph.D., chairman and CEO of ZeaVision L.L.C. "For the 17 million already suffering from macular degeneration, that
means new hope and the promise of a better quality of life — hope that extends to the millions of others who face the very real
possibility of developing this hereditary disease."
Available without a prescription, ZeaVision comes in two dosages: a 10 mg supplement for people who have been diagnosed with or are
at increased risk for macular degeneration, and a 3 mg supplement for people at low or no risk who want to maintain healthy zeaxanthin levels.
"Zeaxanthin occurs naturally in foods such as corn, oranges, eggs and certain leafy green vegetables. Unfortunately, it's difficult to meet
the body's requirements through diet alone, although doing so may be critical to eye health," says Steven N. Frank, vice chairman and president
of ZeaVision. "Research has already demonstrated that zeaxanthin may help prevent macular degeneration, and a growing body of scientific
evidence suggests that restoring zeaxanthin levels may slow the disease's progression. But further study is needed, and ZeaVision
actively supports and participates in ongoing research."
ZeaVision has been extensively tested and found to be safe with no known side effects or drug interactions. It is available on
the Company's website at www.zeavision.com or by calling toll-free (888) 875-EYES (3937).
About zeaxanthin
Zeaxanthin, the main component of ZeaVision, occurs naturally in foods such as corn, oranges, eggs and certain leafy green vegetables. Yet it is nearly impossible to meet the body's zeaxanthin requirements by food intake alone. Doing so, however, is critical to eye health.
Many researchers now believe that zeaxanthin provides crucial protection against the high-energy blue wave light that is processed through the macula. It also acts as an antioxidant, protecting the eye's photoreceptor cells and maintaining its ability to keep central vision strong. Further, clinical research has demonstrated that zeaxanthin may help prevent macular degeneration. Finally, while a growing body of evidence already suggests that restoring zeaxanthin levels may help slow the progression of the disease, further study is needed. To that end, ZeaVision actively participates in and supports ongoing research on zeaxanthin.
"In short, ZeaVision acts like 'nature's sunglasses,' shielding the eyes while allowing them to repair and heal," says ZeaVision Vice Chairman and President Steven N. Frank. "For the more than 17 million people already suffering from macular degeneration and the nearly 500,000 new patients diagnosed each year, that means new hope and the promise of a better quality of life."
About ZeaVision, LLC
Based in St. Louis, ZeaVision, LLC (www.zeavision.com) developed and markets ZeaVision, a dietary supplement containing zeaxanthin and formulated to help prevent and/or impede the progression of macular degeneration. The Company holds three U.S. patents on the ZeaVision formula, which is available without a prescription in both 10mg and 3mg supplements.
Media Contact
Liz Roop
RFB Communications Group, Inc.
(813) 259-0345
email
April 1, 2002
ZeaVision, LLC Launches Zeaxanthin-based Supplement To Help Combat Macular Degeneration
ST. LOUIS — (April 1, 2002) — ZeaVision, LLC today launched ZeaVision, a patent-protected dietary supplement containing
zeaxanthin, a critical nutrient that may slow and even help prevent macular degeneration, the leading cause of blindness
in people age 55 and older.
ZeaVision is the only product on the market able to deliver sufficient levels of zeaxanthin to the macula, where it helps
repair and protect the eye from the damaging effects of aging and the most harmful rays of light.
Available without a prescription, ZeaVision comes in two dosages: a 10mg supplement for people who have been diagnosed
with or are at increased risk of macular degeneration, such as family history of the disease, as well as a 3mg supplement
for people with low or no known risk factors for macular degeneration who want to maintain healthy levels of zeaxanthin.
"The diagnosis of macular degeneration is so devastating because, until now, there was very little that could be done as the
disease slowly robbed patients of both their precious sight and their quality of life," says Dennis L. Gierhart, Ph.D., Chairman
and CEO of ZeaVision, LLC. "The launch of ZeaVision is so deeply satisfying to us because it represents new hope for those
suffering from this disease. It also represents more than a decade of collaboration by eye care professionals, scientists,
vision loss foundations and business partners."
ZeaVision, LLC currently holds three U.S. patents on the ZeaVision formula, which has been extensively tested and found to
be safe with no known side effects or drug interactions.
ZeaVision is available for purchase on the Company's web site at www.zeavision.com or by calling toll-free (888) 875-3937 (EYES).
About zeaxanthin
Zeaxanthin, the main component of ZeaVision, occurs naturally in foods such as corn, oranges, eggs and certain leafy green vegetables. Yet it is nearly impossible to meet the body's zeaxanthin requirements by food intake alone. Doing so, however, is critical to eye health.
Many researchers now believe that zeaxanthin provides crucial protection against the high-energy blue wave light that is processed through the macula. It also acts as an antioxidant, protecting the eye's photoreceptor cells and maintaining its ability to keep central vision strong. Further, clinical research has demonstrated that zeaxanthin may help prevent macular degeneration. Finally, while a growing body of evidence already suggests that restoring zeaxanthin levels may help slow the progression of the disease, further study is needed. To that end, ZeaVision actively participates in and supports ongoing research on zeaxanthin.
"In short, ZeaVision acts like 'nature's sunglasses,' shielding the eyes while allowing them to repair and heal," says ZeaVision Vice Chairman and President Steven N. Frank. "For the more than 17 million people already suffering from macular degeneration and the nearly 500,000 new patients diagnosed each year, that means new hope and the promise of a better quality of life."
About ZeaVision, LLC
Based in St. Louis, ZeaVision, LLC (www.zeavision.com) developed and markets ZeaVision, a dietary supplement containing zeaxanthin and formulated to help prevent and/or impede the progression of macular degeneration. The Company holds three U.S. patents on the ZeaVision formula, which is available without a prescription in both 10mg and 3mg supplements.
Media Contact
Liz Roop
RFB Communications Group, Inc.
(813) 259-0345
email
|
|